Enhancing the efficacy of cancer vaccines in urologic oncology: new directions

@article{Kusmartsev2009EnhancingTE,
  title={Enhancing the efficacy of cancer vaccines in urologic oncology: new directions},
  author={Sergei Kusmartsev and Johannes W. Vieweg},
  journal={Nature Reviews Urology},
  year={2009},
  volume={6},
  pages={540-549}
}
Immunotherapeutic interventions have long been utilized in urologic oncology for the treatment of metastatic renal cell or superficial transitional cell carcinoma. Most recently, the first active specific immunotherapeutic approach, a cancer vaccine, has passed the final phase of human testing and its approval by the FDA is pending. However, evidence suggests that the full protective and therapeutic potential of cancer vaccines has not yet been achieved. Through multiple mechanisms, tumors… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Cancer Stem Cell Resistance to Targeted Therapy

  • Resistance to Targeted Anti-Cancer Therapeutics
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 112 REFERENCES

A randomized, double‐ blind, placebo‐controlled, multi‐center, phase III trial of sipuleucel‐T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) [abstract LBA9

Schellhammer, F P.
  • Presented at the American Urological Association Annual Meeting [online],
  • 2009

Altered expression of 15 ‐ hydroxyprostaglandin dehydrogenase in tumor ‐ infiltrated CD 11 b myeloid cells : a mechanism for immune evasion in cancer

e. eruslanov
  • J . Immunol .
  • 2009